Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib vs tocilizumab in pediatric systemic juvenile idiopathic arthritis
jRCT2031230402Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2024
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of upadacitinib in systemic juvenile idiopathic arthritis (SJIA) (3 cohorts), sponsored by AbbVie Inc. Primary endpoint: Adapted sJIA ACR30 response. Started Aug 2024; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)
Beyond the preview
Go deeper on jRCT2031230402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230402.